⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
N-Acetylcysteine (NAC)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-10 — Antioxidant Therapy, N-acetyl-L-cysteine, Effects on Pancreatic Beta Cells: Therapeutic Promise or Potential Harm?: 2026 narrative review reframes NAC’s beta-cell effects as context-dependent: protective under obesity/high-fat-diet/T2D oxidative stress, but potentially harmful via reductive stress disrupting ROS-dependent insulin signaling in normal and aging beta cells — benefit/harm hinges on redox state, metabolic context, and dose (review of preclinical and mechanistic literature, no new primary data). [mechanism-plausible] (novelty: 3)
- 2026-06-15 — Glycine Supplementation Improves Cognitive Performance in Mexican Older Adults: cross-connection with glycine: Glycine is one half of the GlyNAC combination (glycine + NAC) studied for aging biomarkers; this trial isolates glycine alone at a much lower dose, useful for parsing which effects belong to which component. (novelty: 3)
Open questions
Related
Contributing findings
Antioxidant Therapy, N-acetyl-L-cysteine, Effects on Pancreatic Beta Cells: Therapeutic Promise or Potential Harm?
10-oct-2026
novelty 3
per-area 3
strengthens
A Staged Translational Framework for Evaluating Oral Glutamatergic and Senescence-Modulating Strategies in Treatment-Resistant Depression.
24-aug-2026
novelty 2
per-area 2
mentions
A minimal three-arm oral regimen for healthspan: mechanistic alignment with transcriptomic signals from a large parental-lifespan GWAS.
19-aug-2026
novelty 2
per-area 2
introduces
From antioxidant to senotherapeutic: Repurposing n-acetylcysteine to counteract senescence via the HuR pathway in human endothelial cells.
31-jul-2026
novelty 2
per-area 2
introduces